Program
pemigatinib
Also written as “Pemigatinib”.
Its studies are mostly in Cholangiocarcinoma · Carcinoma, Transitional Cell · Glioblastoma · Neoplasms, Unknown Primary · Myeloproliferative Disorders, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Incyte | 131 open or running | phase 3since Aug 29, 2018 | Jan 30, 2015 | Feb 25, 2031phase 2 · NCT07862998 |
| Innovent Biologics | 20 open or running | phase 2since Jan 20, 2020 | Jan 20, 2020 | none ahead |
| Hoffmann-La Roche | 10 open or running | phase 2since Apr 5, 2018 | Apr 5, 2018 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 30, 2015First study: phase 2 study in Lung NeoplasmsNew to IncyteIncyte · NCT02393248 · 201 enrolled · United States, Denmark
- Aug 16, 2016Phase 2 study in Carcinoma, Transitional CellIncyte · NCT02872714 · 263 enrolled · United States, Belgium, Denmark and more
- Oct 4, 2016Phase 2 study in CholangiocarcinomaIncyte · NCT02924376 · 147 enrolled · United States, Belgium, France and more
- Jan 4, 2017Phase 2 study in Myeloproliferative DisordersIncyte · NCT03011372 · 47 enrolled · United States, Austria, Belgium and more
- Jul 27, 2017Phase 1 study in NeoplasmsIncyte · NCT03235570 · 44 enrolled · Japan
- Apr 5, 2018Hoffmann-La Roche's first study: phase 2 study in Neoplasms, Unknown PrimaryNew to Hoffmann-La RocheHoffmann-La Roche · NCT03498521 · 529 enrolled · Australia, Austria, Brazil and more
- Aug 29, 2018Phase 3 study in CholangiocarcinomaIncyte · NCT03656536 · 167 enrolled · United States, Austria, Belgium and more
- Jan 28, 2019Phase 2 study in AcrocephalosyndactyliaIncyte · NCT03822117 · 111 enrolled · United States, Denmark, France and more
- Jun 25, 20192 phase 2 studiesIncyte · NCT04003623, NCT04003610
- Jan 20, 2020Innovent Biologics's first study: phase 1 study in Solid TumorNew to Innovent BiologicsInnovent Biologics · NCT04258527 · 12 enrolled · China
- Jan 20, 2020Phase 2 study in CholangiocarcinomaInnovent Biologics · NCT04256980 · 34 enrolled · China
- Jun 25, 2021Phase 2 study in Advanced MalignanciesIncyte · NCT04949191 · 10 enrolled · United States, Denmark, Italy and more
- Feb 14, 20222 phase 2 studiesIncyte · NCT05253807, NCT05267106
- Oct 2, 2026Phase 2 study in CholangiocarcinomaIncyte · NCT07862998 · 72 planned
Ahead
- Feb 25, 2031Primary completion: phase 2 study in CholangiocarcinomaIncyte · NCT07862998
TargetBeta
“An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3), ”NCIt, by rule
“Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| infigratinibrule | BridgeBio | phase 3 | 17 |
| futibatinibrule | Otsuka | phase 3 | 10 |
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07862998Cholangiocarcinoma | 2 | Not yet recruiting | Incyte | Feb 25, 2031 | 72 |
| NCT05267106Glioblastoma · United States, Denmark, France and more | 2 | Terminated | Incyte | Dec 17, 2024 | 83 |
| NCT05253807Carcinoma, Non-Small-Cell Lung · United States, France, Germany and more | 2 | Completed | Incyte | Aug 16, 2023 | 8 |
| NCT04949191Advanced Malignancies · United States, Denmark, Italy and more | 2 | Terminated | Incyte | Apr 11, 2024 | 10 |
| NCT04258527Solid Tumor · China | 1 | Completed | Innovent Biologics | Jul 2, 2020 | 12 |
| NCT04256980Cholangiocarcinoma · China | 2 | Completed | Innovent Biologics | Jan 29, 2021 | 34 |
| NCT04003610Carcinoma, Transitional Cell · United States, Austria, Belgium and more | 2 | Terminated | Incyte | Apr 18, 2021 | 7 |
| NCT04003623Neoplasm Metastasis · United States | 2 | Terminated | Incyte | Jun 12, 2020 | 1 |
| NCT03822117Acrocephalosyndactylia · United States, Denmark, France and more | 2 | Terminated | Incyte | Mar 29, 2022 | 111 |
| NCT03656536Cholangiocarcinoma · United States, Austria, Belgium and more | 3 | Terminated | Incyte | Jul 7, 2025 | 167 |
| NCT03498521Neoplasms, Unknown Primary · Australia, Austria, Brazil and more | 2 | Completed | Hoffmann-La Roche | Feb 14, 2023 | 529 |
| NCT03235570Neoplasms · Japan | 1 | Completed | Incyte | Mar 4, 2020 | 44 |
| NCT03011372Myeloproliferative Disorders · United States, Austria, Belgium and more | 2 | Completed | Incyte | Oct 30, 2024 | 47 |
| NCT02924376Cholangiocarcinoma · United States, Belgium, France and more | 2 | Completed | Incyte | Feb 1, 2022 | 147 |
| NCT02872714Carcinoma, Transitional Cell · United States, Belgium, Denmark and more | 2 | Completed | Incyte | Feb 1, 2022 | 263 |
| NCT02393248Lung Neoplasms · United States, Denmark | 2 | Terminated | Incyte | Dec 17, 2021 | 201 |
How it is read
Names in the registry
- “Pemigatinib”, 15 entries
- “pemigatinib”, 2 entries
Conditions, from the studies’ own filings
- Cholangiocarcinoma, 4 studies
- Carcinoma, Transitional Cell, 2 studies
- Glioblastoma, 1 study
- Neoplasms, Unknown Primary, 1 study
- Myeloproliferative Disorders, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.